



CONSEGNA
DELIVERING INNOVATION

SHAREHOLDER UPDATE

HIGHLIGHTS:

- Turbine manufacturing underway and launch update
- Change of company name to Rhinomed™ to reflect focus on nasal technology
- Divestment of 75m IMU shares

Melbourne, Australia – September 19, 2013

In February this year we put in place the first phase of a strategy that will fundamentally reform operations and put the company on a sound footing to achieve future revenues and financial stability.

Our objective in effecting a complete transformation of the company and focusing on the opportunities presented by the BreatheAssist™ nasal technology reflects the significant opportunities identified in a range of markets.

MAJOR DEVELOPMENTS

TURBINE™ MANUFACTURING

As recently announced, the company appointed ChinaMed as our manufacturing partner. We can now report that manufacturing of the Turbine has now commenced at the ChinaMed facility. A recent visit to the facility confirmed that ChinaMed are capable of producing the Turbine product at both the highest quality and at volume and importantly, are also well placed to work with the company as we expand our programs in Sleep, Wellbeing and Drug delivery.

TURBINE Launch

The company is now readying for the launch of our first product – The Turbine - in November of this year. We will shortly be inviting all shareholders to pre order a Turbine from the new website, please notify the company of your contact details if you wish to receive an invitation to sample the product ahead of launch.

COMPANY BRANDING

The company is focused on creating a global technology brand based on our BreatheAssist nasal technology.

The board and management team reviewed the current company branding and came to the conclusion that the current name did not reflect the company's future nor would assist with the creation of significant value. As a result the board had resolved to change the name of the company to better reflect our focus on nasal and respiratory technologies.

Subject to shareholder approval at the AGM the company will change its name to Rhinomed. *Why Rhinomed?* As many of you will immediately know Rhinology is the branch of medicine related to the nose. Our clear focus on nasal and respiratory technologies and desire to clearly position the company as a leader in this space makes this choice straightforward.



IMU HOLDING

As shareholders will know, Consegna held a 29% stake (100m shares) in Imugene Limited as a result of the sale of the Linguet asset in August last year. The shares were in escrow until July of this year. We acknowledge that previous management had identified the potential for an in specie distribution of the holding to CGP shareholders if it was practical and the value warranted such an action.

The board had been assessing the alternatives in regards to its holding and as a result, put in place a strategy to realize value of the holding when the opportunity arose.

On Wednesday 18th September, following an announcement by IMU of their decision to discontinue their Ibuprofen program, the opportunity arose to execute the strategy, and therefore we have retained 25m shares in the event that IMU is able to secure a positive future. The proceeds of the share sale will be applied to bolster the working capital of the company as we progress the launch of the Turbine.

Media Enquiries

Michael Johnson, CEO & Executive Director
+61 (03) 9614 3663
mjohnson@consegna.com

About Consegna Group Limited (ASX:CGP)

Consegna is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise application of its BreatheAssist technology portfolio in the Sport, Snoring, Olfactory, Sleep and Drug Delivery markets. For more information go to www.consegna.com

About the Turbine™

The Turbine is a revolutionary product, which utilises the BreatheAssist technology and can deliver to athletes on average 38% increase in airflow through the nasal passages. In a recent athlete user trial, two thirds of respondents reported that when using a Turbine™ prototype they felt they got more air into their lungs and 60% reported that they felt less fatigued during training.

The Turbine product range has been designed for both professional and amateur athletes participating in sports and fitness activities ranging from triathlon, cycling, running and non-impact sports to elite training environments, such as altitude training.